New hope for tough pancreatic cancer? early trial tests immune boosts

NCT ID NCT04787991

Completed Disease control Sponsor: Cancer Insight, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested different combinations of immunotherapy drugs with standard chemotherapy for people with metastatic pancreatic cancer that had not been treated before. The main goal was to check safety and see if the combinations could shrink tumors or control the disease. 45 participants were enrolled in this exploratory study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Stanford University

Stanford, California, 94305, United States
University of California, Los Angeles

Los Angeles, California, 90095, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.